Week's news analysis

FAREVA strengthens in the production of injectable forms with high added value

By The Editor - 23 october 2020

Fareva enters into exclusive negotiations with Novartis to take over the production site in Unterach (Upper Austria), recognized as the center of excellence for the manufacture of injectable cancer drugs.

The Unterach am Attersee plant in Upper Austria develops and manufactures injectable medicinal products. Today the site is the Novartis competence center for injectable anticancer drugs (development and production for Novartis, Sandoz and third-party companies)

The product portfolio includes over 20 different active ingredients that are standard treatment for the most common types of cancer, such as colon, lung, breast or prostate cancer. Comprehensive development skills at the Unterach site ensure continuous expansion of the portfolio. Research activities at the site cover all aspects of drug development - from pharmaceutical development to preclinical studies to approval.

With the acquisition of the Unterach site, Fareva, a global developer and manufacturer of pharmaceutical contracts (CDMO), will further strengthen its presence in the European market, particularly in the field of the manufacture of ready-to-use injectable drugs. The site will continue to produce for the Novartis Group, a corresponding supply agreement is part of the contractual agreement.

The agreement is subject to the approval of regulatory authorities. Novartis and Fareva expect transaction to be formally closed in Q1 2021

Go to Top